docetaxel, gemcitabine, vinorelbine, irinotecan, etoposide, vinblastine, capecitabine, navelbine or pemetrexed; or

ii. the tumor is head and neck cancer, and the additional agent is one or more of paclitaxel, carboplatin, doxorubicin or cisplatin; or

iii. the tumor is a estrogen and/or progesterone positive breast cancer, and the additional agent is one or more of doxorubicin, epirubicin, paclitaxel, nab-paclitaxel, docetaxel, fluorouracil, cyclophosphamide, carboplatin, letrozole, mifepristone, capecitabine, gemcitabine, vinorelbine or tamoxifen; or

iv. the tumor is a pancreatic tumor and the additional agent is nab-paclitaxel, capecitabine, gemcitabine, navelbine or paclitaxel.

66. The method according to any preceding claim, wherein the subject is a human.

67. The method according to any preceding claim, wherein the method comprises inhibiting, reducing or blocking HER2 signaling.

68. The method according to any preceding claim, wherein the method comprises killing or inhibiting the growth of a HER2-expressing tumor cell.

69. The method according to any preceding claim, wherein the subject is administered at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 doses.

70. The method according to any preceding claim, wherein the amount of at least one of the plurality of doses is at least 0.3, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg/kg.

71. The method according to any preceding claim, wherein the amount of each of the plurality of doses is at least 0.3, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg/kg.

72. The method according to any preceding claim, wherein each dose is administered at least daily, weekly, or monthly.

73. The method according to any preceding claim, wherein each dose is administered at least every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 days.

74. The method according to any preceding claim, wherein treatment continues for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days; at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks; or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 months.

75. The method according to any preceding claim, wherein the mean tumor volume in the subject after receiving at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 doses is less than the mean tumor volume of a control subject receiving an equivalent amount of trastuzumab.

76. The method according to any preceding claim, wherein overall survival of the subject is significantly increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment; or wherein the growth of tumor is significantly decreased as compared to a control subject receiving an equivalent amount of a non-specific control antibody, as compared to a control subject receiving an equivalent amount of Herceptin, or as compared to a control subject not receiving treatment.

77. The method of claim **76**, wherein the significance is measured by a log rank test.

78. The method of claim **76**, wherein the p value is less than 0.5, 0.01, or 0.001.

79. The method according to any preceding claim, wherein overall survival of the subject is more significantly increased as compared to a control subject receiving an equivalent amount of trastuzumab.

80. The method of claim **79**, wherein the antigen-binding construct p value is less than 0.001 and wherein the trastuzumab p value is greater than 0.001.

81. The method according to any preceding claim, wherein the p value of the significance of the increase relative to the control subject receiving an equivalent amount of a non-specific control antibody is less than the p value of an increase in survival of a second control receiving an equivalent amount of trastuzumab as compared to the control subject receiving an equivalent amount of a non-specific control antibody.

82. The method of claim **81**, wherein the antigen-binding construct p value is less than 0.001 and wherein the trastuzumab p value is greater than 0.001.

83. The method according to any preceding claim, wherein overall survival of the subject after receiving a combination of the antigen-binding construct and an additional agent is significantly increased as compared to a control subject receiving an equivalent amount of trastuzumab alone.

84. The method according to any preceding claim, wherein overall survival of the subject is significantly increased as compared to a control subject receiving a lesser amount of trastuzumab.

85. A method of treating a subject having a tumor according claim **1** wherein the antigen-binding construct is conjugated to DM1.

86. The method according to claim **86** wherein the tumor is a HER2 3+T-DM1 resistant metastatic breast tumor and wherein the rate of tumor growth following treatment is decreased compared to the tumor growth in an untreated subject.

87. The method according to claim **86** wherein the tumor is an ovarian tumor, and and wherein the rate of tumor growth following treatment is decreased compared to the tumor growth in an untreated subject.

88. The method of claim **88** wherein the subject has a complete response to treatment.

89. The method according to claim **86** wherein the tumor is a HER2 2+ breast tumor, and wherein the rate of tumor growth following treatment is decreased compared to the tumor growth in an untreated subject.

90. The method according to claim **86** wherein the tumor is a HER2 3+ gastric tumor, and wherein the rate of tumor growth following treatment is decreased compared to the tumor growth in an untreated subject.

91. The method of claims **86-91** wherein the antigen-binding construct conjugated to DM1 is v10553.

92. The method of claim **92** wherein the treated subject receives a plurality of doses of the antigen-binding construct of at least 0.3, 0.5, 1, 2, 3, 4 or 5 mg/kg.

93. The method of claims **86-93** wherein the subject receives treatment at least every 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 weeks.

94. The method according to any preceding claim, wherein the subject has previously been treated with tras-